Nuvation Bio grants 123,397 options to director
Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options. The award covers 123,397 options to buy Class A common stock at an exercise price of $4.79 per share, expiring on May 20, 2036.
All of the options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, as long as the director remains in continuous service. Following this grant, the filing shows 123,397 derivative securities held directly, with no open‑market purchases or sales reported.
Insider Trade Summary
Grant/Award: 123,397 shares
Grant/Award
1 txn
Insider
BLICKENSTAFF KIM D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 123,397 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 123,397 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.
Key Figures
Option grant size: 123,397 options
Exercise price: $4.79 per share
Options after transaction: 123,397 derivative securities
+2 more
5 metrics
Option grant size
123,397 options
Stock Option (Right to Buy) granted to director on May 21, 2026 filing date reference
Exercise price
$4.79 per share
Conversion or exercise price for Class A common stock options
Options after transaction
123,397 derivative securities
Total options held following the grant transaction
Option expiration
May 20, 2036
Expiration date of the stock option award
Cliff vesting date
May 21, 2026
100% vesting on earlier of this date or next annual meeting
Key Terms
Stock Option (Right to Buy), Class A Common Stock, derivative securities, vesting
4 terms
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying_security_title": "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative securities financial
"total_shares_following_transaction": "123397.0000""
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vesting financial
"100% of the shares subject to the option shall vest on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nuvation Bio (NUVB) report for Kim D. Blickenstaff?
Nuvation Bio reported a grant of stock options to director Kim D. Blickenstaff for 123,397 shares of Class A common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.
How many Nuvation Bio (NUVB) options were granted and at what price?
The filing shows 123,397 stock options granted with an exercise price of $4.79 per share. These options give the director the right to buy Nuvation Bio Class A common stock at that fixed price in the future.
When do the newly granted Nuvation Bio (NUVB) options vest?
All granted options vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting. Vesting is conditioned on Kim D. Blickenstaff maintaining continuous service with Nuvation Bio through the applicable vesting date.
Did the Nuvation Bio (NUVB) Form 4 show any stock sales or purchases?
The Form 4 reports an acquisition of stock options as a grant or award and no open-market purchases or sales. It records one derivative transaction, increasing the director’s option holdings without changing common shares held through market trading.
What is the expiration date of the Nuvation Bio (NUVB) options granted?
The granted stock options expire on May 20, 2036, according to the Form 4. After this expiration date, any unexercised options will lapse and no longer give the right to buy Nuvation Bio Class A common stock at $4.79.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates